key: cord-0957619-uey15pw2
authors: Iwanaga, Naoki; Cooper, Laura; Rong, Lijun; Maness, Nicholas J.; Beddingfield, Brandon; Qin, Zhongnan; Crabtree, Jackelyn; Tripp, Ralph A.; Yang, Haoran; Blair, Robert; Jangra, Sonia; García-Sastre, Adolfo; Schotsaert, Michael; Sruti, Chandra; Robinson, James E.; Srivastava, Akhilesh; Rabito, Felix; Qin, Xuebin; Kolls, Jay K.
title: ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
date: 2021-12-20
journal: iScience
DOI: 10.1016/j.isci.2021.103670
sha: 314b82c9fd47db0e1feac4f7c08722030cf3a14f
doc_id: 957619
cord_uid: uey15pw2

SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. A mutation in the catalytic domain of ACE2, MDR504, significantly increased binding to SARS-CoV-2 spike protein, as well as to a spike variant, in vitro with more potent viral neutralization in plaque assays. Parental administration of the protein showed stable serum concentrations with excellent bioavailability in the epithelial lining fluid of the lung, and ameliorated lung SARS-CoV-2 infection in vivo. These data support that the MDR504 hACE2-Fc is an excellent candidate for treatment or prophylaxis of COVID-19 and potentially emerging variants.

SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor . Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung (Lei et al., 2020) . To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. MDR503 has a R273A mutation, MDR504 has a H345A mutation, and MDR505 has the R273A/H345A mutation.

This fusion protein contained a LALA mutation that abrogates Fcr binding but retains FcRN binding. A mutation in the catalytic domain of ACE2, MDR504, had significantly increased binding to SARS-CoV-2 spike protein, as well as to several spike variants, in vitro with more potent viral neutralization in a plaque assay. These data were independently validated by

The Coronavirus Immunotherapy Consortium (CoVIC). Parental administration of the MDR504 protein showed stable serum concentrations with excellent bioavailability in the epithelial lining fluid of the lung, and ameliorated lung SARS-CoV-2 infection in vivo.

Moreover, MDR504 retained binding to several emerging SARS-CoV-2 variants. These data support that the MDR504 hACE2-Fc is an excellent candidate for treatment or prophylaxis of J o u r n a l P r e -p r o o f

In addition to the wild-type (WT) ACE2 ectodomain, we engineered several mutations in the catalytic domain and named these MDR503, MDR504 and MDR505. Constructs included an IgG leader sequence and an IEGR linker between ACE2 and the CH2 and CH3 domains of human IgG1 ( Figure S1A ). Also, schematic overviews of the hACE2-Fc and MDR504 are depicted by Raptor X ( Figure S1B ) (Xu et al., 2008) .

All constructs of hACE2-Fc expressed proteins consistent with homodimers after transfection in HEK293T cells. After transient transfection of the constructs in 293T cells, human IgG-Fc in the supernatant was readily detected by ELISA (data not shown). Proteins were run on a reduced SDS-PAGE gel and migrated at ~ 140 kDa consistent with the predicted molecular weight of the monomer ( Figure S1C ). Also, SDS-PAGE analysis in nonreducing conditions revealed migration consistent with a dimeric protein ( Figure S1D ).

In experiments performed at room temperature, we observed higher binding of the MDR504 and MDR505 ACE2-Fc compared to WT ACE2-Fc ( Figure 1A & 1B) . This increase in binding was more dramatic when assayed at 37 0 C ( Figure 1C & 1D) where binding of the MDR504 mutant was superior against the monomeric spike RBD protein from ATCC. To test whether the MDR504 mutant lacked ACE2 catalytic activity we performed an in vitro catalysis assay using a fluorogenic peptide that contains an ACE2 cleavage site. Using this assay, WT ACE2 showed substantial catalysis of the peptide whereas the MDR504 mutant completely lacked any detectable activity ( Figure 1E ). Using a pseudotyped model of SARS-CoV-2 we found superior neutralization with the MDR504 and MDR505 compared to WT hACE2 Fc ( Figure S2A & S2B). The dose response curve showed the excellent neutralization by MDR505 (WT hACE2; 8.58 nM vs MDR505 hACE2; 2.01 nM) ( Figure S2C & S2D) . Next, we examined neutralization of SARS-CoV-2 (Wuhan-Hu-1; GenBank: MN_908947) using a plaque assay in Vero E6 cells. 50 μg/ml WT J o u r n a l P r e -p r o o f hACE2-Fc completely neutralized SARS-CoV-2 in vitro (data not shown). Thus, we compared the wild-type protein to the MDR503, MDR504 and MDR505 at lower concentrations. Here, MDR504 and MDR505 efficiently neutralized virus infection and had lower IC50s than the wild-type protein (Figure 2A & 2B) .

We deposited MDR504 in the COVID database (https://covic.lji.org/databases/) and they found that this protein has a Kd of 1.62 x 10 -9 using the full-length D614 ectodomain and a Kd of 8.03 x 10 -10 against the full-length D614G ectodomain (Table S1 ). Thus, the MDR504 and MDR505 mutation may have a structural basis for enhanced neutralization over WT hACE2-Fc and that will be the subject of future research. Based on the lower IC50 of MDR504 against authentic SARS-CoV-2 virus (Wuhan-Hu-1; GenBank: MN_908947) we prioritized this protein for in vivo testing as well as in vitro binding to SARS-CoV-2 variants (Table S2 ).

After a single IV injection, the MDR504 mutant had similar serum stability as WT hACE2-Fc ( Figure 3A ) and we detected higher tendency in the epithelial lining fluid of the lung after parenteral administration to C57BL/6J mice, but that was not significant ( Figure 3B ). The MDR504 mutant had a slightly higher peak concentration in serum and a half-life of approximately 145 h. We next tested the efficacy of engineered hACE2-Fc in our recently established mild to moderate COVID-19 mouse model, namely, SARS-CoV-2-infected mice that are induced to express hACE2 via delivery of adeno 5-drived hACE2 viruses to their lung (Ad5-hACE2) (Han et al., 2020; Sun et al., 2020) . Mice were untreated or dosed intravenously with 15 mg/kg with human polyclonal IgG1, WT hACE2-Fc, or MDR504 four hours prior to SARS-CoV-2 infection for a prophylaxis model. Histological analysis of untreated, human IgG1 treated, and WT hACE2-Fc treated Ad5-hACE2 mice showed similar widespread SARS-CoV-2 infection in the distal lung with approximately 4% of the cell area J o u r n a l P r e -p r o o f infected (naïve lung (%); 4.32 ± 0.37, human IgG1 treated lung (%); 3.59 ± 0.80, WT hACE2-Fc treated lung (%); 4.29 ± 0.80). In contrast, MDR504 had significantly less infected cell area positive for SARS-CoV-2 staining (MDR504 hACE2-Fc treated lung (%); 0.64 ± 0.37) ( Figure 4A & 4B) . Also, we performed RNA scope, which is an RNA ISH technology with a unique probe design strategy that allows simultaneous signal amplification and background suppression to achieve single-molecule visualization while preserving tissue morphology. RNA scope for viral RNA showed significant fewer infected cells in MDR504 treatment ( Figure 4C ). We checked the viral load, but it was not significant due to the sample variances ( Figure S3 ). We speculate some of this signal likely represented the viral inoculum. Additionally, MDR504 lacks FCR binding and thus viral RNA may be sequestered virus whereas the viral protein staining is a more accurate measure of the number of lung cells actually infected. Of note, infection with SARS-CoV-2 induces interferon stimulated chemokines such as Cxcl9 and Cxcl10 similar to infected human lung (Liao et al., 2020) .

Notably, in MDR504 treated Ad5-hACE2 mice the Cxcl9 gene expression was relatively reduced by RNA Scope ( Figure 4C ) and the Cxcl9 and Cxcl10 gene expression was substantially down-regulated by RT-PCR ( Figure 4D , 4E).

We next examined MDR504 in treatment models in which we administered the proteins post SARS-CoV-2 challenge. Based on more potent binding of the CHO protein by ELISA ( Figure   S4A ) and improved pharmacokinetics ( Figure S4B , S4C) of this molecule, we used CHO protein in the treatment model. We confirmed that MDR504 protein produced in CHO had the nearly identical molecular weight as the protein produced in 293T cells ( Figure S4D ). To evaluate treatment, we tested MDR504 in a severe COVID-19 mouse model, namely, K18-hACE2 transgenic mice of SARS-CoV-2 infection model (Yinda et al., 2021) . Before starting the experiment, we confirmed there is significant viral replication in the lung as measured by ~ 10 4 sub-genomic RNA copies in the lung four hours after intranasal administration ( Figure   J o u r n a l P r e -p r o o f S5). As K18-hACE2 mice support significantly higher viral replication than the Ad5-hACE2 model, we administered MDR504 or control 4 hours after viral infection and increased the dose to 30 mg/kg body weight. In the high-dose SARS-CoV-2 model, MDR504 substantially suppressed viral load as measured by total and subgenomic N gene expression ( Figure 5A , 5B), dramatically reduced number of the infection cells in the lung, evidenced by SARS-CoV-2 viral staining, a method directly evaluating the severity of the lung infection ( Figure   5C and 5D) (Han et al., 2020) , and inhibited Cxcl9 gene expression ( Figure 5E ), although this was not significant compared to WT hACE2-Fc. Cxcl10 was also assessed but it was not different among the samples ( Figure S6 ). This could be due to the rapid induction of patients (Ackermann et al., 2020; O'Sullivan et al., 2020) . Vcam1 is a surrogate marker for assessing endothelial dysfunction (Liao, 2013) . MDR504 treatment significantly downregulated the expression of the Vcam1, on pulmonary endothelial cells ( Figure 5H ), indicating the treatment protects the pulmonary endothelial cells from SARS-CoV-2 infection-mediated dysfunction and injury, which could be one of the multiple reasons for the benefit on the prolonged survival.

Lastly, we tested MDR504 binding to several spike variants ( Table S2 ) that have been associated with reduced binding by casirivimab, imdevimab, or bamlanivimab Liu et al., 2020; Starr et al., 2021) . MDR504 retained pM binding to these variants ( Figure 6A ) with only mildly reduced binding to V483A ( Figure 6B ). We observed enhanced binding of MDR504 to ACE2 to variants Y453F as well as HV69-70del / N501Y / D614G that were identified in the SARS-CoV-2 variant ( Figure 6A ). We also observed increased binding to the alpha variant, first detected in the UK (B.1.1.7) ( Figure 6D ) that was significantly J o u r n a l P r e -p r o o f shifted to the left compared to wild-type ACE2 ( Figure 6C ). Binding to the beta variant, first detected in South Africa (B.1.351) ( Figure 6E ) was also significantly higher with MDR504 versus wild-type ACE2. Moreover, using a microneutralization assay we established the IC50 of MDR504 against different SARS-CoV-2 variants including two variants of concern as well as recombinant viruses that have either the E484K (rE484K) or K417N, E484K and N501Y (rTriple) ( Figure 6F 

ACE2 is expressed in the nasal respiratory epithelium, in the conducting airway in type II pneumocytes (Hou et al., 2020) and elsewhere (Hoffmann et al., 2020) . One potential mechanism that has made SARS-CoV-2 more infectious than the 2002 SARS-CoV epidemic is the higher affinity of SARS-CoV-2 spike protein to the human ACE2 (Shang et al., 2020; Yan et al., 2020) . However, this increased affinity represents a potential therapeutic target to block viral entry. Recent surface plasmon resonance assays with soluble ACE2 binding SARS-CoV-2 spike protein had a binding affinity in the nM to pM range (Lei et al., 2020) .

Thus, a soluble version of ACE2 may have potent viral neutralization activity. ACE2 is a type I transmembrane protein with a 740 amino acid ectodomain (Crackower et al., 2002) .

Soluble ACE2 has been shown to bind to SARS-CoV and SARS-CoV-2 spike proteins and block viral entry (Monteil et al., 2020) . Soluble ACE2 has been administered to humans with pulmonary hypertension (Hemnes et al., 2018) and acute respiratory distress syndrome (ARDS) (Khan et al., 2017) at dose ranges of 0.1 to 0.8 mg/kg and shown to be well tolerated. However, the pharmacokinetic/pharmacodynamic (PK/PD) of soluble ACE2 is not ideal for sustained viral neutralization in vivo and soluble ACE2 is not engineered to be transported from the circulation into the epithelial lining fluid of the lung. ACE2-IgG Fc fusion J o u r n a l P r e -p r o o f proteins have been reported to also bind virus and neutralize SARS-CoV-2 pseudoviruses in vitro (Lei et al., 2020) . Moreover, several mutants in the catalytic domain have been reported that also bind and neutralize virus (Lei et al., 2020) . However, ACE2-IgG Fc fusion proteins retain FcR binding which may compromise serum stability or activate FcRon myeloid cells, which may be problematic in To this end, we designed and produced hACE2-Fc fusions with mutations in the hACE2 catalytic domain as well as in the IgG1 constant region to abrogate FcRbinding with a LALA mutation, but retain binding to the neonatal Fc receptor which is important for serum stability (Arduin et al., 2015) as well as transport into the lung (Kolls et al., 1995) . All constructs were efficiently secreted after transient transfection in 293T or CHO cells and purified using protein G resin. All proteins bound monomeric SARS-CoV-2 receptor binding domain as well as trimeric spike protein (Amanat et al., 2020) . Initial studies were done at 50 μg/ml (223 nM) based on studies with Pavalizumab, an anti-RSV monoclonal antibody, showed that effective anti-RSV trough concentrations in vivo were ~ 40 μg/ml (Beeler and van Wyke Coelingh, 1989) . Using both pseudovirus and authentic virus, MDR504 showed efficacy against SARS-CoV-2 infection in vitro and in vivo. Moreover, MDR504 appears to maintain potency to several variants of concern.

At this time, the structural basis for this remains unclear. Cryo-EM studies of SARS-CoV-2 RBD has been shown to bind the NH2 terminus of human ACE2 (Lan et al., 2020) . However, the RBD also binds to residues K353, G354, and D355 (Lan et al., 2020) and thus it is possible that the MDR504 mutation in the catalytic domain affects this binding. The other reported hACE2-Fc mutants showed equivalent binding and pseudovirus neutralization (Lei et al., 2020) . The authors of this paper made H374N and H378N mutations that have putatively reduced ACE2 catalytic activity but that was not specifically assayed as part of J o u r n a l P r e -p r o o f their study (Lei et al., 2020) . However, our IC50 data is in agreement with their calculated Kd using surface plasmon resonance where the Kd was reported to be 11.2 nM (Lei et al., 2020) . Prior structural studies suggest that H345 is not only in the catalytic pocket, but very close to the RBD binding site. Analysis in Raptor suggests that H345A may reduce constraint of the alpha-helix that interacts with SARS-CoV-2 spike RBD. Note that the H345A mutation has reduced catalytic activity in the fluorogenic peptide assay used here but retains activity against full length substrate.

Taken together, this reagent may be useful as pre-and post-exposure prophylaxis or as therapy for COVID-19 as well as emerging variants of SARS-CoV-2. This technology may also complement vaccine technology, as it may be useful in subjects that may not be good candidates for vaccines such as patients with hematologic or other malignancies, or those that are undergoing immunosuppressive therapy for organ transplantation or autoimmune disease.

This study has several limitations. First, we did not formally evaluate if the mutant ACE2 constructs are immunogenic after single IV administration. Secondly the mode of viral inoculation in K18-ACE2 mice results in rapid infection of the lower respiratory tract which likely reduces the duration of the therapeutic window in this animal model. 

Further information and requests for resources and reagents should be directed to the lead contact, Jay Kolls (jkolls1@tulane.edu).

Requests for materials should be also directed to the lead contact, Jay Kolls (jkolls1@tulane.edu).

Male wild-type C57BL/6J mice or male K18-hACE2 transgenic mice 6-10-week-old were used for in vivo studies. The mice were bred in-house or purchased from The Jackson

Laboratory. All experiments were performed using sex-and age-matched controls and approved by the Institutional Animal Care and Use Committee of Tulane University.

Control and Prevention and sold by BEI Resources, NIAID, NIH. We passaged the virus in VeroE6 cells in DMEM media with 2% FBS and sequenced the virus for verification as described previously (Han et al., 2020) . Mice were intranasally infected by 2 X 10 5 TCID50 SARS-CoV-2 in ABSL3.

All animals were cared for in accordance with the NIH guide to Laboratory Animal Care. The

Institutional Biosafety Committee approved the procedures of sample handling, inactivation, and removal from a BSL3 containment. For a prophylaxis model, we utilized the murine model of SARS-CoV-2 that C57BL/6J mice were first oropharyngeally inoculated with 1.5 x 10 9 pfu adenovirus encoding human ACE2 (Vector Biosystems INC, Malvern, PA) as described our recent publication (Han et al., 2020) . Four days later, mice received 2 x 10 5 pfu of SARS-CoV-2 intranasally and were euthanized 72 hours post infection by the ABSL3 staff. To evaluate MDR504, mice were dosed intravenously via retro-orbital with 15 mg/kg body weight polyclonal human IgG1, WT hACE2-Fc or MDR504 4 hours prior to SARS-CoV-2 infection for prophylaxis model. As a treatment model of high viral load, we confirmed the efficacy using K18-hACE2 transgenic mice, in which we infected 2 x 10 5 pfu SARS-CoV-2 and treated with the 30 mg/kg body weight of the antibodies 4 hours post infection.

The DNA sequences of the extracellular domains of ACE2 and IgG1Fc were synthesized by Genscript and cloned into pcDNA3.1. Iggk hACE2 ED R273A Ig is labeled as MDR503, Iggk hACE2 ED H345A Ig is labeled as MDR504, and Iggk hACE2 ED R273A H345A Ig is labeled as MDR505. Transient transfection was performed using Lipofectamine™ 3000

Transfection Reagent (Invitrogen) in 293T cells. The collected supernatants were collected and purified by protein G-sepharose (Thermo Fisher). Additionally, we utilized MDR504 produced in CHO cells (produced by Lake Pharma, Dallas TX). The concentration and purity were confirmed by measuring the UV absorbance at wavelength of 280 nm, BCA assay (Thermo Fisher) and human IgG ELISA (Thermo Fisher).

Following the removal of the supernatants, cell lysates were dissolved in 50 mg/ml cell lysis buffer (Cell signaling) containing protease inhibitors (Thermo Scientific) and 1 mM PMSF.

BCA assay was performed to quantify protein and 5.0 μg protein was used for Western blotting. Western blots were performed using 7.5% SDS-PAGE gels (Bio-Rad) under the non-reducing or reducing condition with 2.5% 2-mercaptoethanol and transferred to PVDF membranes. The blot was probed with goat anti-human IgG-HRP (Southern Biotech). After incubation with IgG-HRP-conjugated anti-human antibody, membranes were washed and incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).

Signal was detected using Bio-Rad ChemiDoc MP imaging system.

ELISA plates were coated with 2 μg/mL recombinant S1 subunit, receptor binding domain Absorbance was read at 450 nm on a microplate reader (BioTek). Various mutant spike variants were examined for binding with WT hACE2-Fc and MDR504 (Table S2) .

The SARS-CoV-2 pseudovirus was generated using the following plasmids: Relative light units (RLU) were measured in a Biotek Synergy H1 Luminometer. The RLU data were analyzed in GraphPad prism to determine IC50 for each reagent and plasma.

Vero E6 cells were plated in a 6 well plate at 8 x 10 5 cells per well and incubated overnight.

Each construct of hACE2-Fc was preincubated with SARS-CoV-2 (L strain of Wuhan-Hu-1;

GenBank: MN_908947) for 10 minutes before infection in 1 ml media. The cells were washed once with PBS and infected at a MOI of 0.01 with the compounds for 1 h. Following infection, the supernatants containing the virus and compounds were removed and 3 ml overlay media containing each compound were added to the wells and incubated for additional 4 days. Post infection, the cells were fixed and stained to visualize plaques.

C57BL/6J mice were injected with 4 mg/kg body weight WT hACE2-Fc or the MDR504 mutant intravenously via retro-orbital and serum was collected at 0, 1, 24, or 72 h. Mice were euthanized at 6h and 72 h and underwent bronchoalveolar lavage (BAL) to measure hACE2-

Fc in the epithelial lining fluid of the lung. The concentration of hACE2-Fc was analyzed by detecting human IgG-Fc by ELISA. We used purified anti-human IgG Fc antibody (Biolegend) as a capture antibody and anti-Human IgG Fc, Multi-Species SP ads-HRP (SouthernBiotech) as a detection antibody and the other procedure is same as mentioned above.

Lung tissues were collected in Zinc formalin (Anatech), embedded in paraffin and 5 μm thick sections were cut, adhered to charged glass slides, baked overnight at 56 0 C and passed through Xylene, graded ethanol, and double distilled water to remove paraffin and rehydrate tissue sections. A microwave was used for heat induced epitope retrieval. Slides were heated in a high pH solution (Vector Labs H-3301), rinsed in hot water and transferred to a heated low pH solution (Vector Labs H-3300) where they were allowed to cool to room temperature. Sections were washed in a solution of phosphate-bufferred saline and fish gelatin (PBS-FSG) and transferred to a humidified chamber. Tissue was blocked with 10 % normal goat serum (NGS) for 40 minutes, followed by 60 minutes incubation with the first antibodies (Table S3 ). Slides were transferred to the humidified chamber and incubated, for 40 minutes, with secondary antibodies tagged with various Fluor fluorochromes and diluted to a working concentration of 2 μg/mL (Table S3) J o u r n a l P r e -p r o o f

RNA was isolated with RNeasy Plus Mini Kit (QIAGEN) post phase separation using Trizol reagent (ThermoFisher), and cDNA was prepared using iScript reverse transcriptase master mix (Bio-Rad). Real-time RT-PCR was carried out with Bio-Rad CFX96 system using TaqMan PCR Master Mix (ThermoFisher Scientific) and Cxcl9 or Cxcl10 premixed primers/probe sets from Thermo Fisher Scientific. Subgenomic mRNA (sgmRNA) encoding the N gene or total N gene was quantified using a published assay (Wolfel et al., 2020) . The viral copy numbers from the lung samples are represented as copies/100ng of RNA.

Z-fix-fixed and paraffin-embedded lung sections underwent in situ hybridization according to the manufacturer's instructions (Advanced Cell Diagnostics, Inc). Briefly, after hydrogen peroxide treatment, we performed target retrieval, created a hydrophobic barrier, and applied AP conjugated-nCoV2019-S probe (RNAscope® Probe V-nCoV2019-S, ACD cat# 848561) and Cxcl9 probe (RNAscope® Probe Mm-Cxcl9-C2, ACD cat# 489341-C2) for hybridization. After hybridization, tissues were stained with 50% Hematoxylin. in 5% non-fat milk in 1xPBS+ 0.1% Tween-20 for 1 hour at room temperature. After blocking, the cells were incubated with anti-SARS-CoV-2 NP and anti-spike monoclonal antibodies, mixed in 1:1 ratio, for 1.5 hours at room temperature. Cells were washed in 1xPBS and incubated with 1:5000 diluted HRP-conjugated anti-mouse IgG secondary antibody for 1 hour at RT followed by a brief PBS wash. Finally, 100μl tetramethyl benzidine (TMB)

substrate was added and incubated at RT until blue color appeared, and the reaction was terminated with 50μl 1M H2SO4. Absorbance was recorded at 450nm and 650nm as a reference and percentage reduction in infection was calculated as compared to negative control. SEM. Significant differences are designated using one-way ANOVA followed by Tukey's multiple comparisons test. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001 (n = 3-4, representative from 2 independent experiments). 

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

A serological assay to detect SARS-CoV-2 seroconversion in humans

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Lung Expression of Human ACE2 Sensitizes the Mouse to SARS-CoV-2 Infection

A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Linking endothelial dysfunction with endothelial cell activation

Single-cell landscape of bronchoalveolar immune cells in patients with COVID

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Endothelial cells orchestrate COVID-19 coagulopathy

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity

Structural basis of receptor recognition by SARS-CoV-2

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Virological assessment of hospitalized patients with COVID-2019

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Protein structure prediction using threading

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections

This work was supported by the following NIH grant R35HL139930 (JK) and R21OD024931(XQ) as well as a grant form Emergent Ventures and the Paul Bechtner Foundation (JK) . This work was also partly supported by CRIP (Center for Research York) for providing us the spike proteins including variants of concern. We thank Randy Albrecht for support with the BSL3 facility and procedures at the ISMMS.